title: Hepatoprotective effects of syringin on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice.
abstract: The prognosis for fulminant hepatic failure (FHF) still remains extremely poor with a high mortality and, therefore, better treatments are urgently needed. Syringin, a main active substance isolated from Eleutherococcus senticosus, has been reported to exhibit immunomodulatory and anti-inflammatory properties. In this study, we investigated the effects and underlying mechanisms of syringin on lipopolysaccharide (LPS) and D-galactosamine (D-GalN)-induced FHF in mice. Mice were administered syringin (10, 30 and 100 mg kg(-1), respectively) intraperitoneally (i.p) 30 min before LPS/D-GalN then mortality and liver injury were evaluated subsequently. We found that syringin dose-dependently attenuated LPS/D-GalN-induced FHF, as indicated by reduced mortality, inhibited aminotransferase and malondialdehyde (MDA) content, an increased glutathione (GSH) concentration and alleviated pathological liver injury. In addition, syringin inhibited LPS/D-GalN-induced hepatic caspase-3 activation and hepatocellular apoptosis, myeloperoxidase (MPO) activity and intercellular adhesion molecule-1 (ICAM-1) expression, as well as hepatic tissues tumor necrosis factor-alpha (TNF-α) production and NF-κB activation in a dose-dependent manner. These experimental data indicate that syringin might alleviate the FHF induced by LPS/D-GalN through inhibiting NF-κB activation to reduce TNF-α production.
authors.affiliation: Department of Anatamy, Chongqing Medical University, Chongqing, 400016, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Gong
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Rong
authors.initials: R
authors.lastname: Jiang
authors.forename: Chang-Dong
authors.initials: CD
authors.lastname: Wang
authors.forename: Xin-Ru
authors.initials: XR
authors.lastname: Yin
authors.forename: Jing-Yuan
authors.initials: JY
authors.lastname: Wan
mesh_terms: D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D028001:Eleutherococcus / Q000737:chemistry; D005688:Galactosamine / Q000633:toxicity*; D005960:Glucosides / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000633:toxicity*; D017114:Liver Failure, Acute / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008111:Liver Function Tests; D051379:Mice; D008807:Mice, Inbred BALB C; D010666:Phenylpropionates / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D020011:Protective Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D005960:Glucosides; D008070:Lipopolysaccharides; D010666:Phenylpropionates; D020011:Protective Agents; C440499:lipopolysaccharide, Escherichia coli O111 B4; D005688:Galactosamine; C028305:syringin
keywords: TNF-α; apoptosis; fulminant hepatic failure; lipopolysaccharide; syringin